However in this study, TLR4/MyD88 co-expression showed a predilection for serous neoplasms in general, particularly borderline and malignant serous tumours, and was expressed in both high- and low-grade serous carcinomas. The gene discussed is TLR4; the disease is serous adenocarcinoma.